{
  "retracted": false,
  "timestamp": 1556150400000,
  "updates": [
    {
      "timestamp": 1587685233172,
      "identifier": {
        "doi": "10.1007/s10637-019-00773-9"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s10637-019-00755-x"
  },
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial"
}
